Nasus Pharma Ltd Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Nasus Pharma Ltd (NSRX) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $2.56 million as of 2025-06-30, per its 6-K filed 2025-12-29.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2026-03-25
- 2025-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $2.56M.
- 2024-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $1.80M.
- 2024-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $3.16M.
- 2023-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $1.83M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2025-06-30 | $2.56M 6-K · filed 2025-12-29 |
| 2024-12-31 | $1.80M 20-F · filed 2026-03-25 |
| 2024-06-30 | $3.16M 6-K · filed 2025-12-29 |
| 2023-12-31 | $1.83M 20-F · filed 2026-03-25 |
| 2022-12-31 | $1.05M 20-F · filed 2026-03-25 |